PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Nov 14, 2014
SOUTH PLAINFIELD, N.J., Nov. 14, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) received the Outstanding Innovation Award at The 2014 Rare & Orphan Advocacy & Research Awards for Translarna™, the first treatment approved in the European Union for Duchenne muscular dystrophy. The Rare & Orphan Advocacy & Research (ROAR) Awar...
Nov 13, 2014
SOUTH PLAINFIELD, N.J., Nov. 13, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its 2nd Annual Science Day on Monday, November 24, 2014 from 8:00 a.m. to 12:00 p.m. ET at the Le Parker Meridien in New York City. Members of PTC's senior management and research teams will provide a corporate update and in...
Nov 6, 2014
SOUTH PLAINFIELD, N.J., Nov. 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ended September 30, 2014. "During the quarter we continued to make significant progress during this transformative time for PTC. For the first time in the company'...
Nov 3, 2014
SOUTH PLAINFIELD, N.J., Nov. 3, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been approved to be included in the list of drugs reimbursable by the Italian National Health System under Law 648/96. The decision is expected to be formalized through its publication in the official Ital...
Oct 29, 2014
SOUTH PLAINFIELD, N.J., Oct. 29, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Credit Suisse 23rd Annual Healthcare Conference on Tuesday, November 11th at 4:30 pm MT at the Arizona Biltmore in Phoenix, Arizona. The presentation will be webcast live on the Even...
Oct 27, 2014
SOUTH PLAINFIELD, N.J., Oct. 27, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of data and related analysis which provide strong support for concluding that Translarna™ (ataluren) was active and showed clinically meaningful improvements in Translarna-treated patients with nonsense mutation Duchenne...
Oct 23, 2014
SOUTH PLAINFIELD, N.J., Oct. 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2014 financial results and provide an update on the company's business and outlook on Thursday, November 6, 2014 at 9:00 a.m. (ET) before the opening of the mark...
Oct 9, 2014
SOUTH PLAINFIELD, N.J., Oct. 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a public offeri...
Oct 8, 2014
SOUTH PLAINFIELD, N.J., Oct. 8, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it is commencing an underwritten public offering of 3,000,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission. All of the...
Sep 24, 2014
SOUTH PLAINFIELD, N.J., Sept. 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1st at 8:25 am ET at Le Parker Meridien in New York City. The presentation will be webcast live on the Events and ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue